Anxiety disorders are common and disabling conditions, with a lifetime prevalence of 17% in the general population. Due to high rates of treatment resistance, there is interest in new pharmacological treatment options. Second-generation antipsychotic drugs may be a helpful treatment for anxiety disorders. This Cochrane review looked at RCTs comparing quetiapine, olanzapine and risperidone with placebo [read the full story…]